Arvinas Presents Preclinical Data on Protein Degrader, ARV-471, at the 2018 San Antonio Breast Cancer Symposium (SABCS)

Author's Avatar
Dec 08, 2018
Article's Main Image

ARV-471 Degraded Estrogen Receptor and Provided Improved Anti-Tumor Activity When Compared to SOC, Both as a Monotherapy and in Combination